抗血小板药物治疗急性冠脉综合征研究进展被引量：7

下载PDF

导出

摘要急性冠脉综合征（acute coronary syndrome,ACS）是以冠状动脉粥样硬化斑块破裂、血栓形成,导致管腔完全或不完全闭塞的一组临床综合征。血小板激活介导的血栓形成是ACS的主要病理生理机制,血小板激活、聚集在其发生发展中起着关键作用。因此,抗血小板贯穿急性冠脉综合征治疗的始终。

作者顾颖杨雅薇李攀张云雁艾热夏提张建马丽萍

机构地区第二军医大学长海医院心血管内科

出处《临床军医杂志》 CAS 2016年第5期529-533,共5页 Clinical Journal of Medical Officers

基金国家自然科学基金面上项目(81170223/H0212)

关键词抗血小板血栓形成急性冠脉综合征

分类号 R543.3 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献32

1Mehta SR,Tanguav JF,Eikelbom Jw,et al.Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes(CURRENT-OASIS 7):a randomised factorial trial[J].Lancet,2010,376(9748):1233-1243.
2Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines onmyocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].Eur Heart J,2014,35(37):2541-2619.
3Emmanuel Saltiel,Alan Ward.Ticlopidine:A review of its pharmacodynamics and pharmacokinetic properties,and therapeutic efficacy in platelet-dependent disease states[J].Drugs,1987,34(2):222-262.
4Bonello L,Tantry US,Marcucci R,et al.Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J].J Am Coll Cardiol,2010,56(12):919-933.
5Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation[J].N Engl J Med,2001,345(23):494-502.
6Ferri N,Corsini A,Bellosta S.Pharmacology of the new P2Y12receptor inhibitors:Insights on pharmacokinetic and pharmacodynamic properties[J].Drugs,2013,73(15):1681-1709.
7赵青,张抒扬.氯吡格雷抵抗的早期诊断及临床对策[J].中华临床医师杂志（电子版）,2012,6(2):128-130. 被引量：14
8Butler K,Teng R.Pharmacokinetics,pharmacodynamics,safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers[J].Br J Clin Pharmacol,2010,70(1):65-77.
9Holmberg MT,Tornio A,Joutsi-Korhonen L,et al.Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects[J].Br J Clin Pharmacol,2013,75(6):1488-1496.
10Teng R,Oliver S,Hayes MA,et al.Absorption,distribution,metabolism,and excretion of ticagrelor in healthy subjects[J].Drug Metab Dispos,2010,38(9):1514-1521.

<12 3 4 >

二级参考文献98

1韩雅玲,王守力,李毅,荆全民,马颖艳,王祖禄,王冬梅,栾波,王效增.急性冠状动脉综合征患者冠状动脉支架术前高负荷量氯吡格雷预治疗近期疗效[J].中国介入心脏病学杂志,2005,13(1):9-12. 被引量：53
2Jeffrey S. Berger,Maria C. Roncaglioni,Fausto Avanzini,Ierta Pangrazzi,Gianni Tognoni,David L. Brown,崔艳丽（译）,赵秀丽（校）.阿斯匹林在男性和女性心血管事件一级预防中的应用——随机对照试验性别特异性汇总分析[J].美国医学会杂志（中文版）,2006,25(5):275-282. 被引量：40
3Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿（译）,David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志（中文版）,2007,26(3):131-139. 被引量：59
4Mehta SR,Yusuf S,Peters RJ,et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:The pci-cure study.Lancet,2001,358:527-533.
5Angiolillo DJ,Suryadevara S,Capranzano P,et al.Antiplatelet drug response variability and the role of platelet function testing:A practical guide for interventional cardiologists.Catheter Cardiovasc Interv,2009,73:1-14.
6Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogrel for coronary stenting:Response variability,drug resistance,and the effect of pretreatment platelet reactivity.Circulation,2003,107:2908-2913.
7Giorgi MA,Di Girolamo G,Gonzalez CD.Nonresponders to clopidogrel:Pharmacokinetics and interactions involved.Expert Opin Pharmacother,2010,11:2391-2403.
8Ford NF.Clopidogrel resistance:Pharmacokinetic or pharmacogenetic?J Clin Pharmacol,2009,49:506-512.
9Malek LA,Kisiel B,Spiewak M,et al.Coexisting polymorphisms of p2y12and cyp2c19genes as a risk factor for persistent platelet activation with clopidogrel.Circ J,2008,72:1165-1169.
10Gresele P,Falcinelli E,Loffredo F,et al.Platelets release matrix metalloproteinase-2in the coronary circulation of patients with acute coronary syndromes:Possible role in sustained platelet activation.Eur Heart J,2011,32:316-325.